{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:15:52Z","timestamp":1781349352306,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12325-024-02989-5","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T21:05:43Z","timestamp":1726779943000},"page":"4172-4190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis"],"prefix":"10.1007","volume":"41","author":[{"given":"Jesse","family":"Fishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yestle","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6471-9936","authenticated-orcid":false,"given":"Eric M.","family":"Bercaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"2989_CR1","unstructured":"Sheth GS, Chopra S. Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults. In Lindor KD and Robson KM (Ed), UpToDate. 2022."},{"key":"2989_CR2","unstructured":"American Liver Foundation. Nonalcoholic Fatty Liver Disease (NAFLD) 2024 [updated May 16th, 2024]. Available from: https:\/\/liverfoundation.org\/for-patients\/about-the-liver\/diseases-of-the-liver\/non-alcoholic-fatty-liver-disease\/"},{"key":"2989_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:5.","journal-title":"Hepatology"},{"key":"2989_CR4","unstructured":"New MASLD Nomenclature | AASLD 2024. Available from: https:\/\/www.aasld.org\/new-masld-nomenclature"},{"issue":"2","key":"2989_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0035-1550065","volume":"35","author":"P Angulo","year":"2015","unstructured":"Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin Liver Dis. 2015;35(2):132\u201345.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2989_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265\u201373.","journal-title":"J Hepatol"},{"issue":"1","key":"2989_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"key":"2989_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101167","volume":"50","author":"V Ajmera","year":"2021","unstructured":"Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021;50: 101167.","journal-title":"Mol Metab"},{"issue":"11","key":"2989_CR9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep4.1814","volume":"5","author":"N Alkhouri","year":"2021","unstructured":"Alkhouri N, Tincopa M, Loomba R, et al. What does the future hold for patients with nonalcoholic steatohepatitis: diagnostic strategies and treatment options in 2021 and beyond? Hepatol Commun. 2021;5(11):1810\u201323.","journal-title":"Hepatol Commun"},{"issue":"2","key":"2989_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2): 100067.","journal-title":"JHEP Rep"},{"key":"2989_CR11","unstructured":"MP C, NH A. Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations.: UpToDate; [April 8, 2022]. Available from: https:\/\/www.uptodate.com\/contents\/noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-tests-and-imaging-examinations"},{"issue":"6","key":"2989_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199760","volume":"13","author":"YH Yen","year":"2018","unstructured":"Yen YH, Kuo FY, Kee KM, et al. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS ONE. 2018;13(6): e0199760.","journal-title":"PLoS ONE"},{"issue":"2","key":"2989_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","volume":"69","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Tampi R, Priyadarshini M, et al. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology. 2019;69(2):564\u201372.","journal-title":"Hepatology"},{"key":"2989_CR14","unstructured":"J.C. F, C. Q, Y. K, et al. Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study. J Manag Care Spec Pharm. 2024:1\u201313."},{"issue":"1","key":"2989_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/13696998.2023.2184967","volume":"26","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Bonafede M, Fishman J, et al. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis. J Med Econ. 2023;26(1):348\u201356.","journal-title":"J Med Econ"},{"issue":"11","key":"2989_CR16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/03007995.2023.2262926","volume":"39","author":"J Fishman","year":"2023","unstructured":"Fishman J, Tapper EB, Dodge S, et al. The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data. Curr Med Res Opin. 2023;39(11):1425\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"2989_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","volume":"71","author":"JF Dufour","year":"2022","unstructured":"Dufour JF, Anstee QM, Bugianesi E, et al. Current therapies and new developments in NASH. Gut. 2022;71(10):2123\u201334.","journal-title":"Gut"},{"key":"2989_CR18","unstructured":"Madrigal Pharmaceuticals Inc. Rezdiffra (resmetirom): Highlights of prescribing information. West Conshohocken, PA: Madrigal Pharmaceuticals, Inc.; 2024."},{"issue":"2","key":"2989_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eprac.2021.12.010","volume":"28","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Henry L. Fatty liver through the ages: nonalcoholic steatohepatitis. Endocr Pract. 2022;28(2):204\u201313.","journal-title":"Endocr Pract"},{"issue":"11","key":"2989_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/apt.15679","volume":"51","author":"R Loomba","year":"2020","unstructured":"Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020;51(11):1149\u201359.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2989_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5009\/gnl20127","volume":"15","author":"M Soumya","year":"2021","unstructured":"Soumya M, Aijaz A, Donghee K. Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver. 2021;15(2):206\u201316.","journal-title":"Gut Liver"},{"key":"2989_CR22","first-page":"89","volume":"2","author":"J Fishman","year":"2024","unstructured":"Fishman J, O\u2019Connell T, Parrinello C, et al. Prevalence of nonalcoholic steatohepatitis and associated fibrosis stages among US adults, using imaging- vs biomarker-based non-invasive tests. JHEOR. 2024;2:89.","journal-title":"JHEOR."},{"issue":"6","key":"2989_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force\u20131. Value Health. 2012;15(6):796\u2013803.","journal-title":"Value Health."},{"key":"2989_CR24","unstructured":"U.S. Census Bureau. Table H-01. Health Insurance Coverage Status and Type of Coverage by Selected Characteristics for All People: 2021 2022. Available from: https:\/\/www2.census.gov\/programs-surveys\/cps\/tables\/hi\/2022\/h_01.xlsx"},{"key":"2989_CR25","unstructured":"State Health Access Data Assistance Center. Health Insurance Coverage Type by Age 2023. Available from: https:\/\/statehealthcompare.shadac.org\/table\/4\/health-insurance-coverage-type-by-age"},{"key":"2989_CR26","unstructured":"Centers for Medicare & Medicaid Services. Medicare Beneficiaries USE of MEDICARE SERVICES - (Year reported: 2019) 2021 [August 31, 2023]. Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Beneficiary-Snapshot\/Downloads\/Bene_Snaphot.pdf"},{"issue":"5","key":"2989_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528\u201362.","journal-title":"Endocr Pract"},{"key":"2989_CR28","unstructured":"Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis | Madrigal Pharmaceuticals 2024. Available from: https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-initiates-maestro-nash-outcomes-study"},{"key":"2989_CR29","unstructured":"American Heart Association. What Is Metabolic Syndrome? 2021. URL: https:\/\/www.heart.org\/-\/media\/Files\/Health-Topics\/Answers-by-Heart\/What-Is-Metabolic-Syndrome.pdf."},{"key":"2989_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.869190","volume":"9","author":"JS Lee","year":"2022","unstructured":"Lee JS, Lee HW, Kim BK, et al. Comparison of fibroscan-aspartate aminotransferase (FAST) Score and other non-invasive surrogates in predicting high-risk non-alcoholic steatohepatitis criteria. Front Med (Lausanne). 2022;9: 869190.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2989_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u201373.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2989_CR32","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"key":"2989_CR33","unstructured":"Loomba R, Harrison SA, Taub RA, et. Utility of FIB-4, MRE, MRI-PDFF, & FibroScan to identify patients with at-risk F2\/F3 NASH based on screening data from a 2000 patient biopsy-confirmed cohort of resmetirom phase 3 clinical trial (MAESTRO-NASH). American Association for the Study of Liver Disease. The Liver Meeting, Washington DC, November 4\u20138 2022. URL: https:\/\/www.aasld.org\/the-liver-meeting\/utility-fib-4-mre-mri-pdff-and-fibroscan-identify-patients-risk-f2-f3-nash-based."},{"issue":"11","key":"2989_CR34","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919\u201328.","journal-title":"Nat Med"},{"issue":"1","key":"2989_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.17734","volume":"59","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Ratziu V, Anstee QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024;59(1):51\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"2989_CR36","doi-asserted-by":"crossref","unstructured":"Fishman J, Hubbert A, Van der Pluijm W, et al. An epidemiological estimate of the prevalence of the coded nonalcoholic steatohepatitis (NASH) population in the us using an administrative claims dataset. ISPOR Europe. 2022.","DOI":"10.1016\/j.jval.2022.09.945"},{"issue":"3","key":"2989_CR37","first-page":"155","volume":"15","author":"RS Brown Jr","year":"2019","unstructured":"Brown RS Jr. Current management of thrombocytopenia in chronic liver disease. Gastroenterol Hepatol (N Y). 2019;15(3):155\u20137.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"2989_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74(1):474\u201382.","journal-title":"Hepatology"},{"issue":"2","key":"2989_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep4.1618","volume":"5","author":"J Vieira Barbosa","year":"2021","unstructured":"Vieira Barbosa J, Lai M. Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol Commun. 2021;5(2):158\u201367.","journal-title":"Hepatol Commun"},{"key":"2989_CR40","unstructured":"JA T, K S, SM F, et al. Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH); evidence report. Institute for Clinical and Economic Review. May 25, 2023."},{"key":"2989_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjhci-2021-100510","volume":"29","author":"O Yasar","year":"2022","unstructured":"Yasar O, Long P, Harder B, et al. Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). BMJ Health Care Inform. 2022;29:1.","journal-title":"BMJ Health Care Inform."},{"issue":"5","key":"2989_CR42","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1665-2681(19)31317-1","volume":"12","author":"A Said","year":"2013","unstructured":"Said A, Gagovic V, Malecki K, et al. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol. 2013;12(5):758\u201365.","journal-title":"Ann Hepatol"},{"issue":"11","key":"2989_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260320","volume":"16","author":"W Eskridge","year":"2021","unstructured":"Eskridge W, Vierling JM, Gosbee W, et al. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS ONE. 2021;16(11): e0260320.","journal-title":"PLoS ONE"},{"issue":"1","key":"2989_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-023-02726-2","volume":"23","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Krieger N, Przybysz R, et al. The burden of nonalcoholic steatohepatitis (NASH) in the United States. BMC Gastroenterol. 2023;23(1):109.","journal-title":"BMC Gastroenterol"},{"key":"2989_CR45","unstructured":"US Census Bureau. National Population Projections Datasets of the US Census Bureau [2023.05.23]. Available from: https:\/\/www.census.gov\/"},{"key":"2989_CR46","doi-asserted-by":"crossref","unstructured":"Rochon H, Qian C, Bogdanov A, et al. Characterizing the prevalence of nonalcoholic steatohepatitis in the US using two independent real-world cohorts. AMCP 2023.","DOI":"10.1016\/S0016-5085(24)04199-4"},{"issue":"1","key":"2989_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s43441-022-00440-x","volume":"57","author":"T Oka","year":"2023","unstructured":"Oka T, Narukawa M. Emergence of new drugs for intractable diseases is associated with an increase in the number of patients diagnosed thereafter with those intractable diseases. Ther Innov Regul Sci. 2023;57(1):70\u20138.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"2989_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643\u201354.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2989_CR49","doi-asserted-by":"crossref","unstructured":"Thompson W. W, Symum H, Sandul A, et al. Vital signs: hepatitis C treatment among insured adults\u2014United States, 2019\u20132020 2022 [cited 71]. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7132e1.htm#suggestedcitation","DOI":"10.15585\/mmwr.mm7132e1"},{"issue":"1","key":"2989_CR50","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1038\/s41598-024-54441-x","volume":"14","author":"E Dong","year":"2024","unstructured":"Dong E, Nixon K, Gardner LM. A population level study on the determinants of COVID-19 vaccination rates at the US county level. Sci Rep. 2024;14(1):4277.","journal-title":"Sci Rep"},{"key":"2989_CR51","unstructured":"Lakdawalla D, Goldman D, Michaud P-C, et al. Global pharmaceutical policy model (GPPM) technical appendix 2007."},{"key":"2989_CR52","unstructured":"Ward AS, Van Nuys K, Lakdawalla D. Impacts of first-in-class drug approvals on future in-class innovation. USC Schaeffer. 2022."},{"issue":"2","key":"2989_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1475-6773.13591","volume":"56","author":"PD Jacobs","year":"2021","unstructured":"Jacobs PD, Kronick R. The effects of coding intensity in medicare advantage on plan benefits and finances. Health Serv Res. 2021;56(2):178\u201387.","journal-title":"Health Serv Res"},{"key":"2989_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5600\/mmrr.004.02.sa06","volume":"4","author":"R Kronick","year":"2014","unstructured":"Kronick R, Welch WP. Measuring coding intensity in the medicare advantage program. Medicare Medicaid Res Rev. 2014;4:2.","journal-title":"Medicare Medicaid Res Rev"},{"key":"2989_CR55","unstructured":"Levitt L, Biniek JF, Kronick R, et al. Unpacking the controversy over medicare advantage: kaiser family foundation; 2023. Available from: HWS-Medicare-Advantage-Transcript.pdf (kff.org)"},{"key":"2989_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10920277.2023.2281471","volume":"25","author":"A Stocking","year":"2023","unstructured":"Stocking A, Duncan I, Huynh N. Estimating underdiagnosis of patients in chronically ill populations. North Am Actuarial J. 2023;25:1\u201310.","journal-title":"North Am Actuarial J."},{"key":"2989_CR57","unstructured":"Porter D. Direct-to-Consumer (DTC) Pharmaceutical marketing: impacts and policy implications. School of public, nonprofit and health administration review. 2011;7."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02989-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02989-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02989-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:10:35Z","timestamp":1729015835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02989-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2989"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02989-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jesse Fishman was previously an employee of Madrigal Pharmaceuticals, Inc. and previously owned stock options from Madrigal Pharmaceuticals, Inc. Yestle Kim is an employee of Madrigal Pharmaceuticals, Inc., and may own stocks\/and or options from Madrigal Pharmaceuticals Inc. Michael R. Charlton has received advisory and consulting honoraria from Madrigal, Novo Nordisk, Cytodyn, Terns, Alnylam, AMR, Glympse, Northsea, Sagmimet, Genentech, and Merck; he has also received research grants from Pfizer and Madrigal, unrelated to this work. Eric M. Bercaw and Tom O\u2019Connell are employees of Medicus Economics, LLC. Medicus Economics, LLC received consulting fees for research from Madrigal Pharmaceuticals, Inc. Zachary J. Smith was previously an employee of Medicus Economics, LLC at the time of development of this manuscript. Medicus Economics, LLC received consulting fees for research from Madrigal Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This manuscript is based on previously conducted studies and does not contain any new studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}